Logo image of VYGR

VOYAGER THERAPEUTICS INC (VYGR) Stock Fundamental Analysis

NASDAQ:VYGR - Nasdaq - US92915B1061 - Common Stock - Currency: USD

3.14  -0.08 (-2.48%)

After market: 3.14 0 (0%)

Fundamental Rating

3

VYGR gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 551 industry peers in the Biotechnology industry. While VYGR has a great health rating, there are worries on its profitability. VYGR has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

VYGR had negative earnings in the past year.
In the past year VYGR has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: VYGR reported negative net income in multiple years.
VYGR had negative operating cash flow in 4 of the past 5 years.
VYGR Yearly Net Income VS EBIT VS OCF VS FCFVYGR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

1.2 Ratios

VYGR has a better Return On Assets (-23.98%) than 74.77% of its industry peers.
With a decent Return On Equity value of -31.06%, VYGR is doing good in the industry, outperforming 76.04% of the companies in the same industry.
Industry RankSector Rank
ROA -23.98%
ROE -31.06%
ROIC N/A
ROA(3y)-2.66%
ROA(5y)-6.13%
ROE(3y)-14.78%
ROE(5y)-19.08%
ROIC(3y)N/A
ROIC(5y)N/A
VYGR Yearly ROA, ROE, ROICVYGR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VYGR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VYGR Yearly Profit, Operating, Gross MarginsVYGR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

7

2. Health

2.1 Basic Checks

VYGR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VYGR has been increased compared to 1 year ago.
VYGR has more shares outstanding than it did 5 years ago.
VYGR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
VYGR Yearly Shares OutstandingVYGR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
VYGR Yearly Total Debt VS Total AssetsVYGR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

VYGR has an Altman-Z score of -0.13. This is a bad value and indicates that VYGR is not financially healthy and even has some risk of bankruptcy.
With a decent Altman-Z score value of -0.13, VYGR is doing good in the industry, outperforming 62.43% of the companies in the same industry.
VYGR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.13
ROIC/WACCN/A
WACC11.13%
VYGR Yearly LT Debt VS Equity VS FCFVYGR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

VYGR has a Current Ratio of 6.10. This indicates that VYGR is financially healthy and has no problem in meeting its short term obligations.
VYGR has a Current ratio of 6.10. This is in the better half of the industry: VYGR outperforms 61.89% of its industry peers.
A Quick Ratio of 6.10 indicates that VYGR has no problem at all paying its short term obligations.
VYGR's Quick ratio of 6.10 is fine compared to the rest of the industry. VYGR outperforms 62.79% of its industry peers.
Industry RankSector Rank
Current Ratio 6.1
Quick Ratio 6.1
VYGR Yearly Current Assets VS Current LiabilitesVYGR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for VYGR have decreased strongly by -2820.00% in the last year.
Looking at the last year, VYGR shows a very negative growth in Revenue. The Revenue has decreased by -43.77% in the last year.
VYGR shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -5.18% yearly.
EPS 1Y (TTM)-2820%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-165%
Revenue 1Y (TTM)-43.77%
Revenue growth 3Y28.85%
Revenue growth 5Y-5.18%
Sales Q2Q%-66.83%

3.2 Future

The Earnings Per Share is expected to decrease by -0.68% on average over the next years.
VYGR is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -3.32% yearly.
EPS Next Y-91.02%
EPS Next 2Y-22.94%
EPS Next 3Y-10.31%
EPS Next 5Y-0.68%
Revenue Next Year-57.23%
Revenue Next 2Y-12.53%
Revenue Next 3Y-7.48%
Revenue Next 5Y-3.32%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VYGR Yearly Revenue VS EstimatesVYGR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
VYGR Yearly EPS VS EstimatesVYGR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VYGR. In the last year negative earnings were reported.
Also next year VYGR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VYGR Price Earnings VS Forward Price EarningsVYGR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VYGR Per share dataVYGR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A cheap valuation may be justified as VYGR's earnings are expected to decrease with -10.31% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-22.94%
EPS Next 3Y-10.31%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VYGR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VOYAGER THERAPEUTICS INC

NASDAQ:VYGR (8/8/2025, 8:11:53 PM)

After market: 3.14 0 (0%)

3.14

-0.08 (-2.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-04 2025-08-04/amc
Earnings (Next)11-10 2025-11-10/amc
Inst Owners64.02%
Inst Owner Change0.8%
Ins Owners0.92%
Ins Owner Change2.77%
Market Cap173.77M
Analysts87.78
Price Target16.32 (419.75%)
Short Float %6.79%
Short Ratio4.55
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-36.79%
Min EPS beat(2)-57.86%
Max EPS beat(2)-15.73%
EPS beat(4)2
Avg EPS beat(4)12.19%
Min EPS beat(4)-57.86%
Max EPS beat(4)65.43%
EPS beat(8)6
Avg EPS beat(8)80.18%
EPS beat(12)8
Avg EPS beat(12)90.86%
EPS beat(16)10
Avg EPS beat(16)73.56%
Revenue beat(2)0
Avg Revenue beat(2)-58.03%
Min Revenue beat(2)-62.87%
Max Revenue beat(2)-53.19%
Revenue beat(4)2
Avg Revenue beat(4)48.38%
Min Revenue beat(4)-62.87%
Max Revenue beat(4)206.51%
Revenue beat(8)6
Avg Revenue beat(8)109.69%
Revenue beat(12)8
Avg Revenue beat(12)102.96%
Revenue beat(16)9
Avg Revenue beat(16)70.44%
PT rev (1m)0%
PT rev (3m)17.43%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-23.47%
EPS NY rev (1m)0%
EPS NY rev (3m)-26.42%
Revenue NQ rev (1m)0.02%
Revenue NQ rev (3m)-37.27%
Revenue NY rev (1m)-0.01%
Revenue NY rev (3m)-41.61%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.6
P/FCF N/A
P/OCF N/A
P/B 0.64
P/tB 0.64
EV/EBITDA N/A
EPS(TTM)-1.46
EYN/A
EPS(NY)-1.71
Fwd EYN/A
FCF(TTM)-2.06
FCFYN/A
OCF(TTM)-2.02
OCFYN/A
SpS1.21
BVpS4.93
TBVpS4.93
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -23.98%
ROE -31.06%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-2.66%
ROA(5y)-6.13%
ROE(3y)-14.78%
ROE(5y)-19.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 44.8%
Cap/Sales 3.04%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.1
Quick Ratio 6.1
Altman-Z -0.13
F-Score2
WACC11.13%
ROIC/WACCN/A
Cap/Depr(3y)62.66%
Cap/Depr(5y)107.17%
Cap/Sales(3y)3.93%
Cap/Sales(5y)4.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2820%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-165%
EPS Next Y-91.02%
EPS Next 2Y-22.94%
EPS Next 3Y-10.31%
EPS Next 5Y-0.68%
Revenue 1Y (TTM)-43.77%
Revenue growth 3Y28.85%
Revenue growth 5Y-5.18%
Sales Q2Q%-66.83%
Revenue Next Year-57.23%
Revenue Next 2Y-12.53%
Revenue Next 3Y-7.48%
Revenue Next 5Y-3.32%
EBIT growth 1Y-481.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-77.07%
EBIT Next 3Y-18.17%
EBIT Next 5Y-12.61%
FCF growth 1Y-254.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-245.99%
OCF growth 3YN/A
OCF growth 5YN/A